Intrahepatic cholestasis of pregnancy (ICP), the most common pregnancy-related liver disease, is significantly linked to higher rates of several maternal, fetal, and newborn issues…
Three Phase 3 clinical trials testing Akero Therapeutics‘ experimental injection therapy efruxifermin in adults with metabolic dysfunction-associated steatotic liver disease (MASLD) or metabolic dysfunction-associated…
AX-0810, an experimental therapy for biliary atresia and other cholestatic diseases, is expected to enter clinical testing by early next year, according to developer…
Most people with chronic hepatitis B enrolled in a Phase 2b clinical trial were eligible to discontinue their use of standard antiviral medication six…
Note: This story was updated Aug. 20, 2024, to correct that Livdelzi is not a first-in-class therapy for primary biliary cholangitis. The U.S. Food…
A triple treatment combination adding fibrates — a type of medication that has shown promise in primary biliary cholangitis (PBC) — to dual therapy…
A 3-year-old boy with progressive familial intrahepatic cholestasis type 3 (PFIC3) was safety and effectively treated with a liver transplant from his mother after failing…
Two Phase 3 clinical trials testing pegozafermin in people with metabolic dysfunction-associated steatohepatitis (MASH), a severe manifestation of fatty liver disease, are enrolling participants,…
A team of researchers has developed a new screening system to identify previously unrecognized mutations as the likely cause of Alagille syndrome. In a…
The U.S. Food and Drug Administration (FDA) has given Gigagen the go-ahead to start clinical testing of GIGA-2339, its experimental treatment for hepatitis B…
